ReviewCurrent opinion in lipidology2016
Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease.
Review in Current opinion in lipidology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Course of Pregnancy in a Woman With Familial Chylomicronemia Syndrome Treated With Plozasiran, a Small Interfering RNA Against ApoC3.JIMD reports · 2026Article
- Glycerophospholipid Profiles ofInsects · 2025Article
- Gut opportunistic pathogens contribute to high-altitude pulmonary edema by elevating lysophosphatidylcholines and inducing inflammation.Microbiology spectrum · 2025Article
- High Protein Diet Contributes to Insulin Resistance in Mice via Shaping Gut Microbiota.Microorganisms · 2025Article
- Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD.Antioxidants (Basel, Switzerland) · 2025Review
- Development of anFrontiers in pharmacology · 2025Article
- Polyphenol-mediated microbiome modulation in STEMI patients: a pilot study.Frontiers in medicine · 2025Article
- Article
- Disordered Gut Microbiome and Alterations in Metabolic Patterns Are Associated With Hypertensive Left Ventricular Hypertrophy.Journal of the American Heart Association · 2024Article
- Microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- In Vivo Monitoring of Glycerolipid Metabolism in Animal Nutrition Biomodel-Fed Smart-Farm Eggs.Foods (Basel, Switzerland) · 2024Article
- Cecal metabolomics of 2 divergently selected rabbit lines revealed microbial mechanisms correlated to intramuscular fat deposition.Journal of animal science · 2024Article
- Bayesian dynamic network modelling: an application to metabolic associations in cardiovascular diseases.Journal of applied statistics · 2024Article
- Cardiometabolic Risk: Characteristics of the Intestinal Microbiome and the Role of Polyphenols.International journal of molecular sciences · 2023Review
- Male-Biased Gut Microbiome and Metabolites Aggravate Colorectal Cancer Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Article
- Metabolomic Characteristics of Cecum Contents in High-Fat-Diet-Induced Obese Mice Intervened with Different Fibers.Foods (Basel, Switzerland) · 2023Article
- The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease.International journal of molecular sciences · 2023Review
- The Phospholipase A2 Superfamily: Structure, Isozymes, Catalysis, Physiologic and Pathologic Roles.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purpose of reviewPhospholipids are major constituents in the intestinal lumen after meal consumption. This article highlights current literature suggesting the contributory role of intestinal phospholipid metabolism toward cardiometabolic disease manifestation. RECENT
findingsGroup 1b phospholipase A2 (PLA2g1b) catalyzes phospholipid hydrolysis in the intestinal lumen. The digestive product lysophospholipid, particularly lysophosphatidylcholine (LPC), has a direct role in mediating chylomicron assembly and secretion. The LPC in the digestive tract is further catabolized into lysophosphatidic acid and choline via autotaxin-mediated and autotaxin-independent mechanisms. The LPC and lysophosphatidic acid absorbed through the digestive tract and transported to the plasma directly promote systemic inflammation and cell dysfunction, leading to increased risk of cardiovascular disease and obesity/diabetes. The choline moiety generated in the digestive tract can also be used by gut bacteria to generate trimethylamine, which is subsequently transported to the liver and oxidized into trimethylamine-N-oxide that also enhances atherosclerosis and cardiovascular abnormalities. SUMMARY: Products of phospholipid metabolism in the intestine through PLA2g1b and autotaxin-mediated pathways directly contribute to cardiometabolic diseases through multiple mechanisms. The implication of these studies is that therapeutic inhibition of PLA2g1b and autotaxin in the digestive tract may be a viable approach for cardiovascular and metabolic disease intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.